Improving Outcomes in High-Risk Myelodysplasia: Festina Lente

Hervé Dombret, John F. Seymour, Aleksandra Butrym, Agnieszka Wierzbowska, Dominik Selleslag, Jun Ho Jang, Rajat Kumar, James Cavenagh, Andre C. Schuh, Anna Candoni, Christian Récher, Irwindeep Sandhu, Teresa Bernal del Castillo, Haifa Kathrin Al-Ali, Giovanni Martinelli, Jose Falantes, Richard Noppeney, Richard M. Stone, Mark D. Minden, Heidi McIntyre, Steve Songer, Lela M. Lucy, C. L. Beach, Hartmut Döhner, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Blood. ,vol. 126, pp. 291- 299 ,(2015) , 10.1182/BLOOD-2015-01-621664

P. Wijermans, M. Lübbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, A. Ferrant, Low-Dose 5-Aza-2′-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients Journal of Clinical Oncology. ,vol. 18, pp. 956- 962 ,(2000) , 10.1200/JCO.2000.18.5.956

C Craddock, L Quek, N Goardon, S Freeman, S Siddique, M Raghavan, A Aztberger, A Schuh, D Grimwade, A Ivey, P Virgo, R Hills, T McSkeane, J Arrazi, S Knapper, C Brookes, B Davies, A Price, K Wall, M Griffiths, J Cavenagh, R Majeti, I Weissman, A Burnett, P Vyas, Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia. ,vol. 27, pp. 1028- 1036 ,(2013) , 10.1038/LEU.2012.312

D. A. Pollyea, J. Zehnder, S. Coutre, J. R. Gotlib, L. Gallegos, O. Abdel-Wahab, P. Greenberg, B. Zhang, M. Liedtke, C. Berube, R. Levine, B. S. Mitchell, B. C. Medeiros, Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia Haematologica. ,vol. 98, pp. 591- 596 ,(2013) , 10.3324/HAEMATOL.2012.076414

Guillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, Alessandra Ferrajoli, Jorge Cortes, William G. Wierda, Stefan Faderl, Charles Koller, Gail Morris, Gary Rosner, Andrey Loboda, Valeria R. Fantin, Sophia S. Randolph, James S. Hardwick, John F. Reilly, Cong Chen, Justin L. Ricker, J. Paul Secrist, Victoria M. Richon, Stanley R. Frankel, Hagop M. Kantarjian, Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood. ,vol. 111, pp. 1060- 1066 ,(2008) , 10.1182/BLOOD-2007-06-098061

R Valdez, J Camoriano, V Fauble, R E Tiedemann, Y H Qiu, K R Coombes, M Cardone, E Braggio, H Yin, D O Azorsa, R A Mesa, A K Stewart, R Tibes, J M Bogenberger, S M Kornblau, W E Pierceall, R Lena, D Chow, C-X Shi, J Mantei, G Ahmann, I M Gonzales, A Choudhary, BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies Leukemia. ,vol. 28, pp. 1657- 1665 ,(2014) , 10.1038/LEU.2014.44

F Traina, V Visconte, P Elson, A Tabarroki, A M Jankowska, E Hasrouni, Y Sugimoto, H Szpurka, H Makishima, C L O'Keefe, M A Sekeres, A S Advani, M Kalaycio, E A Copelan, Y Saunthararajah, S T Olalla Saad, J P Maciejewski, R V Tiu, Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. ,vol. 28, pp. 78- 87 ,(2014) , 10.1038/LEU.2013.269

Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland, Rosalie Odchimar-Reissig, Richard M. Stone, Douglas Nelson, Bayard L. Powell, Carlos M. DeCastro, John Ellerton, Richard A. Larson, Charles A. Schiffer, James F. Holland, Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B Journal of Clinical Oncology. ,vol. 20, pp. 2429- 2440 ,(2002) , 10.1200/JCO.2002.04.117

Pierre Fenaux, Ghulam J Mufti, Eva Hellstrom-Lindberg, Valeria Santini, Carlo Finelli, Aristoteles Giagounidis, Robert Schoch, Norbert Gattermann, Guillermo Sanz, Alan List, Steven D Gore, John F Seymour, John M Bennett, John Byrd, Jay Backstrom, Linda Zimmerman, David McKenzie, CL Beach, Lewis R Silverman, None, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncology. ,vol. 10, pp. 223- 232 ,(2009) , 10.1016/S1470-2045(09)70003-8

Thomas Prebet, Zhuoxin Sun, Maria E. Figueroa, Rhett Ketterling, Ari Melnick, Peter L. Greenberg, James Herman, Mark Juckett, Eunice S. Wang, Mitchell R. Smith, Lisa Malick, Elisabeth Paietta, Magdalena Czader, Mark Litzow, Janice Gabrilove, Harry P. Erba, Steven D. Gore, Martin S. Tallman, Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905 Journal of Clinical Oncology. ,vol. 32, pp. 1242- 1248 ,(2014) , 10.1200/JCO.2013.50.3102